Hangzhou Zhongtai Cryogenic Technology (300435) Fundamentals 2026 — P/E 15.8x, Revenue Analysis | SniperIQ
Hangzhou Zhongtai Cryogenic Technology (300435) is a CN-listed Industrials company in Industrial - Machinery with a market capitalization of ¥6.2B, trading at ¥16.14 on the SHZ. This SniperIQ fundamentals page covers Hangzhou Zhongtai Cryogenic Technology's valuation (P/E 15.8x, P/B 1.8x), profitability (net margin 15.1%), revenue (¥2.8B in FY2025), balance-sheet quality, and AI signal context — from live market data, research only.
Full research coverage
- 8-Quarter Revenue & Margin Trend
- Debt Maturity & Coverage
- Peer Valuation Comparison
- Free Cash Flow & Owner Earnings
- AI Signal + Institutional Flow
- DCF Valuation Model
Frequently Asked Questions
What is Hangzhou Zhongtai Cryogenic Technology's market cap?
Hangzhou Zhongtai Cryogenic Technology (300435) has a market capitalization of approximately ¥6.2B, trading at ¥16.14 on the SHZ. Market cap moves with the live share price.
What is Hangzhou Zhongtai Cryogenic Technology's P/E ratio?
Hangzhou Zhongtai Cryogenic Technology's trailing twelve-month P/E ratio is 15.8x, with a price-to-book (P/B) of 1.8x. Valuation multiples are best compared with Industrials sector peers rather than read in isolation.
How profitable is Hangzhou Zhongtai Cryogenic Technology?
Hangzhou Zhongtai Cryogenic Technology runs a net profit margin of 15.1%, a gross margin of 28.4%, and an operating margin of 18.6%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
How much revenue does Hangzhou Zhongtai Cryogenic Technology generate?
Hangzhou Zhongtai Cryogenic Technology reported revenue of ¥2.8B for fiscal year 2025, with net income of ¥450M and earnings per share (EPS) of 1.17. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.
Does Hangzhou Zhongtai Cryogenic Technology pay a dividend?
Hangzhou Zhongtai Cryogenic Technology offers a trailing dividend yield of about 1.5%. Dividend sustainability depends on payout ratio, free cash flow, and earnings stability — all tracked in SniperIQ's fundamentals view.
Is Hangzhou Zhongtai Cryogenic Technology financially healthy?
Hangzhou Zhongtai Cryogenic Technology carries a debt-to-equity ratio of 0.03x and a current ratio of 2.36x, with a market beta of 0.61. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
Is Hangzhou Zhongtai Cryogenic Technology a good stock to buy in 2026?
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For Hangzhou Zhongtai Cryogenic Technology (300435) the key facts are: market cap ¥6.2B, P/E 15.8x, revenue ¥2.8B, 52-week range 15.21-36.5. Weigh valuation, profitability, growth, and balance-sheet strength against Industrials peers and form your own view.
Track Hangzhou Zhongtai Cryogenic Technology's full fundamentals live
Get Hangzhou Zhongtai Cryogenic Technology's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.